ARCHIVES

Gleevec Maintenance Therapy Showed Significant Benefits At Three Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 35 No. 4 | April 27, 2012

Download PDF Visit The Full Archive

Related Articles

Mozobil Plus G-CSF Increases Rate Of Cell Mobilization

September 30, 2005

Commission Seeks Comparative Data on Cervical Cancer

August 16, 1991

MSKCC In Outreach Agreement With Phelps

December 1, 1995

Moyniham Bill Will Direct HHS to Exempt Centers Recognized By NCI From Prospective Payment System

August 15, 1986

I-ELCAP Results Internally Inconsistent, Peter Bach Writes

June 24, 2011

NCI Advisory Group, Other Cancer Meetings

July 25, 1986